Journal of Infection最新文献

{"title":"Plasma MERTK is causally associated with infection mortality","authors":"Michael Drozd ,&nbsp;Fergus Hamilton ,&nbsp;Chew W. Cheng ,&nbsp;Patrick J. Lillie ,&nbsp;Oliver I. Brown ,&nbsp;Natalie Chaddock ,&nbsp;Sinisa Savic ,&nbsp;Khalid Naseem ,&nbsp;Mark M. Iles ,&nbsp;Ann W. Morgan ,&nbsp;Mark T. Kearney ,&nbsp;Richard M. Cubbon","doi":"10.1016/j.jinf.2024.106262","DOIUrl":"10.1016/j.jinf.2024.106262","url":null,"abstract":"<div><h3>Background</h3><p>Infectious diseases are a major cause of mortality in spite of existing public health, anti-microbial and vaccine interventions. We aimed to define plasma proteomic associates of infection mortality and then apply Mendelian randomisation (MR) to yield biomarkers that may be causally associated.</p></div><div><h3>Methods</h3><p>We used UK Biobank plasma proteomic data to associate 2923 plasma proteins with infection mortality before 31st December 2019 (240 events in 52,520 participants). Since many plasma proteins also predict non-infection mortality, we focussed on those associated with &gt;1.5-fold risk of infection mortality in an analysis excluding survivors. Protein quantitative trait scores (pQTS) were then used to identify whether genetically predicted protein levels also associated with infection mortality. To conduct Two Sample MR, we performed a genome-wide association study (GWAS) of infection mortality using UK Biobank participants without plasma proteomic data (n = 363,953 including 984 infection deaths).</p></div><div><h3>Findings</h3><p>After adjusting for clinical risk factors, 1142 plasma proteins were associated with risk of infection mortality (false discovery rate &lt;0.05). 259 proteins were associated with &gt;1.5-fold increased risk of infection versus non-infection mortality. Of these, we identified genetically predicted increasing MERTK concentration was associated with increased risk of infection mortality. MR supported a causal association between increasing plasma MERTK protein and infection mortality (odds ratio 1.46 per unit; 95% CI 1.15- 1.85; p = 0.002).</p></div><div><h3>Conclusion</h3><p>Plasma MERTK is causally associated with infection mortality and warrants exploration as a potential therapeutic target.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106262"},"PeriodicalIF":14.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001968/pdfft?md5=63cb4a714a6a9cfc30b449602c92d717&pid=1-s2.0-S0163445324001968-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"16S ribosomal RNA gene amplicons in diagnosis of infectious diseases","authors":"Yu-Xin Bu,&nbsp;Peng Zhou,&nbsp;Wen-Ting Ren,&nbsp;Lin Xu,&nbsp;Hong Cheng,&nbsp;Yue-Hong Wu","doi":"10.1016/j.jinf.2024.106263","DOIUrl":"10.1016/j.jinf.2024.106263","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106263"},"PeriodicalIF":14.3,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S016344532400197X/pdfft?md5=f4fc53b5211769aea79fb16e12bb83ea&pid=1-s2.0-S016344532400197X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Looming threat of Mpox in Pakistan: Time to take urgent measures","authors":"Massab Umair,&nbsp;Muhammad Salman","doi":"10.1016/j.jinf.2024.106266","DOIUrl":"10.1016/j.jinf.2024.106266","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106266"},"PeriodicalIF":14.3,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324002007/pdfft?md5=2a1437cdcb8890687f47a86b20480808&pid=1-s2.0-S0163445324002007-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The IL-6 hypothesis in COVID-19: A phase 2, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of free IL-6 sequestration by the monoclonal antibody sirukumab in severe and critical COVID-19","authors":"Robert L. Gottlieb ,&nbsp;Meredith Clement ,&nbsp;Paul Cook ,&nbsp;Audra Deveikis ,&nbsp;Kap Sum Foong ,&nbsp;Philip Robinson ,&nbsp;Jihad Slim ,&nbsp;Cedric W. Spak ,&nbsp;Annemie Buelens ,&nbsp;Katleen Callewaert ,&nbsp;Sandra De Meyer ,&nbsp;Wai Ling Mo ,&nbsp;Inge Verbrugge ,&nbsp;Liesbeth Van Wesenbeeck ,&nbsp;Yanli Zhuang ,&nbsp;Jason W. Chien ,&nbsp;Magda Opsomer ,&nbsp;Erika Van Landuyt","doi":"10.1016/j.jinf.2024.106241","DOIUrl":"10.1016/j.jinf.2024.106241","url":null,"abstract":"<div><h3>Background</h3><p>Upregulation of IL-6 has been associated with worse prognosis in COVID-19 patients. Impact on IL-6 signalling has mostly been limited to clinical outcomes in IL-6 receptor antagonist trials.</p></div><div><h3>Methods</h3><p>We performed a phase 2, randomised, double-blind, placebo-controlled trial (NCT04380961) of US-based hospitalised adults (&lt;85 years) with laboratory-confirmed SARS-CoV-2 infection and severe (low levels of supplemental oxygen) or critical disease (high levels of oxygen supplementation). Patients received sirukumab 5 mg/kg or placebo single dose IV on Day 1 plus standard of care. The primary endpoint was time to sustained clinical improvement up to Day 28 based on an ordinal scale. Secondary endpoints included clinical improvement, all-cause mortality, and safety. Following an interim analysis, the protocol was amended to only recruit patients with critical COVID-19.</p></div><div><h3>Findings</h3><p>From May 2020 to March 2021, 209 patients were randomised; 112 had critical disease (72 sirukumab, 40 placebo) at baseline. Median time to sustained clinical improvement in critical patients was 17 and 23 days in the sirukumab and placebo groups (HR, 1∙1; 95% CI, 0∙66–1∙88; p &gt; 0∙05). At Day 28, 59∙4% versus 55∙0% of patients achieved clinical improvement with sirukumab versus placebo and rates of all-cause mortality were 24∙6% versus 30∙0%, respectively. Rates of grade ≥3 adverse events were comparable between the sirukumab and placebo groups (25∙9% vs 32∙9%; all patients).</p></div><div><h3>Interpretation</h3><p>In critical COVID-19 patients who received sirukumab, there was no statistically significant difference in time to sustained clinical improvement versus placebo despite objective sequestration of circulating IL-6, questioning IL-6 as a key therapeutic target in COVID-19.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106241"},"PeriodicalIF":14.3,"publicationDate":"2024-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001750/pdfft?md5=2bbb6ce2bdbe8d5ae929a5dd9ff79c78&pid=1-s2.0-S0163445324001750-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142057123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Children with hemoglobin C or S trait have low serologic responses to a subset of malaria variant surface antigens","authors":"Rachel D. Bailey ,&nbsp;Jonathan G. Lawton ,&nbsp;Amadou Niangaly ,&nbsp;Emily M. Stucke ,&nbsp;Jason A. Bailey ,&nbsp;Andrea A. Berry ,&nbsp;Amed Ouattara ,&nbsp;Drissa Coulibaly ,&nbsp;Kirsten E. Lyke ,&nbsp;Matthew B. Laurens ,&nbsp;Albert E. Zhou ,&nbsp;Jozelyn Pablo ,&nbsp;Algis Jasinskas ,&nbsp;Rie Nakajima ,&nbsp;Matthew Adams ,&nbsp;Shannon Takala-Harrison ,&nbsp;Bourema Kouriba ,&nbsp;Abdoulaye K. Kone ,&nbsp;Aldiouma Guindo ,&nbsp;J. Alexandra Rowe ,&nbsp;Mark A. Travassos","doi":"10.1016/j.jinf.2024.106257","DOIUrl":"10.1016/j.jinf.2024.106257","url":null,"abstract":"<div><p>Children with hemoglobin AC or AS have decreased susceptibility to clinical malaria. Parasite variant surface antigen (VSA) presentation on the surface of infected erythrocytes is altered in erythrocytes with hemoglobin C (Hb AC) or sickle trait (Hb AS) mutations <em>in vitro</em>. The protective role of incomplete or altered VSA presentation against clinical malaria in individuals with Hb AC or AS is unclear. Using a high-throughput protein microarray, we sought to use serological responses to VSAs as a measure of host exposure to VSAs among Malian children with Hb AC, Hb AS, or wildtype hemoglobin (Hb AA). In uncomplicated malaria, when compared to Hb AA children, Hb AC children had significantly lower serological responses to extracellular <em>Plasmodium falciparum</em> erythrocyte membrane protein-1 (PfEMP1) domains but did not differ in responses to intracellular PfEMP1 domains and other VSAs, including members of the repetitive interspersed family (RIFIN) and subtelomeric variable open reading frame (STEVOR) family. Healthy children with Hb AC and Hb AS genotypes recognized fewer extracellular PfEMP1s compared to children with Hb AA, especially CD36-binding PfEMP1s. These reduced serologic responses may reflect reduced VSA presentation or lower parasite exposure in children with Hb AC or AS and provide insights into mechanisms of protection.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106257"},"PeriodicalIF":14.3,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001919/pdfft?md5=589220a4d5b1f25240cae5224ec2d351&pid=1-s2.0-S0163445324001919-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative effectiveness of bivalent BA.4–5 or BA.1 mRNA booster vaccines among immunocompromised individuals across three Nordic countries: A nationwide cohort study","authors":"Mie Agermose Gram ,&nbsp;Emilia Myrup Thiesson ,&nbsp;Nicklas Pihlström ,&nbsp;Jori Perälä ,&nbsp;Eero Poukka ,&nbsp;Tuija Leino ,&nbsp;Rickard Ljung ,&nbsp;Niklas Worm Andersson ,&nbsp;Anders Hviid","doi":"10.1016/j.jinf.2024.106261","DOIUrl":"10.1016/j.jinf.2024.106261","url":null,"abstract":"<div><h3>Objectives</h3><p>To estimate the effectiveness and waning of the bivalent BA.4–5 or BA.1 mRNA booster vaccine against Covid-19-related hospitalization and death in immunocompromised individuals.</p></div><div><h3>Methods</h3><p>Nationwide analyses across Nordic countries from 1 September 2022 to 31 October 2023 using a matched cohort design. Individuals boosted with a BA.4–5 or BA.1 vaccine were matched 1:1 with unboosted individuals. The outcomes of interest were country-combined vaccine effectiveness (VE) estimates against Covid-19-related hospitalization and death at day 270 of follow-up. Waning was assessed in 45-day intervals.</p></div><div><h3>Results</h3><p>A total of 352,762 BA.4–5 and 191,070 BA.1 booster vaccine doses were included. At day 270, the comparative VE against Covid-19-related hospitalization was 34.2% (95% CI, 7.1% to 61.3%) for the bivalent BA.4–5 vaccine and 42.6% (95% CI, 31.3% to 53.9%) for the BA.1 vaccine compared with matched unboosted. The comparative VE against Covid-19-related death was 53.9% (95% CI, 38.6% to 69.3%) for the bivalent BA.4–5 vaccine and 57.9% (95% CI, 48.5% to 67.4%) for the BA.1 vaccine.</p></div><div><h3>Conclusions</h3><p>In immunocompromised individuals, vaccination with bivalent BA.4–5 or BA.1 booster lowered the risk of Covid-19-related hospitalization and death over a follow-up period of 9 months. The effectiveness was highest during the first months since vaccination with subsequent gradual waning.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106261"},"PeriodicalIF":14.3,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001956/pdfft?md5=7671833fd2a93cfb971be5c9f11db33c&pid=1-s2.0-S0163445324001956-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C","authors":"Thomas R. O'Brien ,&nbsp;David J. Witt ,&nbsp;Varun Saxena ,&nbsp;Kerry Grace Morrissey ,&nbsp;Sabrina Chen ,&nbsp;Francine S. Baker ,&nbsp;Ludmila Prokunina-Olsson ,&nbsp;Ruth M. Pfeiffer ,&nbsp;Jennifer B. Lai","doi":"10.1016/j.jinf.2024.106258","DOIUrl":"10.1016/j.jinf.2024.106258","url":null,"abstract":"<div><h3>Background</h3><p>Shorter duration therapy for hepatitis C virus (HCV) infection might reduce treatment costs and increase the number of patients treated and cured. We determined factors associated with treatment response after an 8-week sofosbuvir-based therapy and developed a simple model to predict an individual’s likelihood of treatment success.</p></div><div><h3>Methods</h3><p>Among 2907 patients who received ledipasvir/sofosbuvir for 8 weeks, we determined failure rates by demographic and clinical characteristics, and <em>IFNL4</em>-∆G/TT genotype. We estimated the average <em>IFNL4</em> genotype-related treatment failure rate in major ancestry groups by applying our <em>IFNL4</em> genotype results to genotype distributions from reference populations. We created a treatment response model based on three personal characteristics.</p></div><div><h3>Results</h3><p>Overall, 4.4% of the patients failed treatment. We observed significantly lower failure rates for persons &lt;50 years (1.6%), females (2.6%), those carrying the <em>IFNL4</em>-TT/TT genotype (1.8%), those with HCV RNA &lt;5.8 log₁₀ copies/mL (2.0%) or HCV genotype-1B infection (2.6%). In a model based on ancestry, age and sex, the predicted probability of treatment failure ranged from 0.5% among females of East Asian ancestry &lt;50 years of age to 8.5% among males of African ancestry age ≥65 years.</p></div><div><h3>Conclusion</h3><p>Applying this algorithm at the point-of-care might facilitate HCV elimination, especially in low- and middle-income countries.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 5","pages":"Article 106258"},"PeriodicalIF":14.3,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001920/pdfft?md5=03e998d5cd0e3ffa3661cca7eb8805e6&pid=1-s2.0-S0163445324001920-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Indirect effectiveness of a novel SAR-COV-2 vaccine (SCB-2019) in unvaccinated household contacts in the Philippines: A cluster randomised analysis","authors":"Asma Binte Aziz ,&nbsp;Jonathan Dewing Sugimoto ,&nbsp;Sye Lim Hong ,&nbsp;Young Ae You ,&nbsp;Lulu Bravo ,&nbsp;Camilo Roa Jr ,&nbsp;Charissa Borja-Tabora ,&nbsp;May Emmeline B. Montellano ,&nbsp;Josefina Carlos ,&nbsp;Mari Rose A. de Los Reyes ,&nbsp;Edison R. Alberto ,&nbsp;Milagros Salvani-Bautista ,&nbsp;Hwa Young Kim ,&nbsp;Irene Njau ,&nbsp;Ralf Clemens ,&nbsp;Florian Marks ,&nbsp;Birkneh Tilahun Tadesse","doi":"10.1016/j.jinf.2024.106260","DOIUrl":"10.1016/j.jinf.2024.106260","url":null,"abstract":"<div><h3>Background</h3><p>Though observational evidence supports indirect effects of SARS-CoV-2 vaccines, randomised experiments are lacking. To address this gap, the double-blinded, prospective follow-up of the household contacts (HHCs) of Philippine participants of the individually-randomised, placebo-controlled trial of the adjuvanted-subunit protein COVID-19 vaccine, SCB-2019, (EudraCT, 2020–004272–17; ClinicalTrials.gov, NCT04672395) was analyzed in a cluster-randomised fashion.</p></div><div><h3>Methods</h3><p>Over an eight-week period, HHCs were followed by rRT-PCR and paired rapid antibody tests (RATs) to detect symptomatic (SCI, primary) and all (ACI, secondary) SARS-CoV-2 infection. A standard analysis estimated the indirect effectiveness of SCB-2019 for each endpoint, excluding HHC RAT-positive at enrollment. A secondary analysis employed enzyme-linked immunosorbent assay (ELISA) results to correct for suspected bias.</p></div><div><h3>Findings</h3><p>SCB-2019 (N = 3470) and placebo (N = 3225) exposed HHCs contributed to at least one analysis. The standard analysis estimated that SCB-2019 reduced the risk of SCI by 83% (95% confidence/credible interval [CI: 32% to 96%), with no effect against ACI. The bias-corrected relative risk reduction was 97% (95% CI: 74% to 100%) for SCI and 79% (95% CI: 14% to 96%) for ACI, with an estimated one SARS-CoV-2 infection prevented per 4.8 households where one member received SCB-2019.</p></div><div><h3>Interpretation</h3><p>SCB-2019 demonstrated bias-corrected indirect effectiveness against SARS-CoV-2 infection among HHC, even at a modest coverage level in the household (approximately 25%). Further research into the indirect effects of SARS-CoV-2 vaccines is needed to optimize the impact of limited doses in low and middle-income settings.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106260"},"PeriodicalIF":14.3,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001944/pdfft?md5=0c4f3fa5d01439bc9517de2f6484e1ec&pid=1-s2.0-S0163445324001944-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased 30-day all-cause mortality associated with Gram-negative bloodstream infections in England during the COVID-19 pandemic","authors":"Taimoor Hasan ,&nbsp;Nina J. Zhu ,&nbsp;Callum Pearson ,&nbsp;Paul Aylin ,&nbsp;Alison Holmes ,&nbsp;Russell Hope","doi":"10.1016/j.jinf.2024.106256","DOIUrl":"10.1016/j.jinf.2024.106256","url":null,"abstract":"<div><h3>Background</h3><p>Our aim was to assess the impact of COVID-19 pandemic on mortality in patients hospitalised with Gram-negative bloodstream infections (GNBSIs).</p></div><div><h3>Methods</h3><p>A retrospective cohort study including cases of <em>Escherichia coli</em>, <em>Klebsiella</em> species and <em>Pseudomonas aeruginosa</em> in England (January 2015–December 2021) reported to UKHSA’s Second Generation Surveillance System. The outcome was 30-day all-cause mortality. Multivariable logistic regression models were built, and adjusted Odds Ratios (ORs) with 95% confidence intervals were reported.</p></div><div><h3>Results</h3><p>Total <em>E. coli</em>, <em>Klebsiella</em> spp. and <em>P. aeruginosa</em> infections were 206,030, 53,819 and 21,129, respectively. Compared to the pre-pandemic period, odds of death during the pandemic (March 2020 onwards) in <em>E. coli</em>, <em>Klebsiella</em> spp. and <em>P. aeruginosa</em> infections with no COVID-19 infection within 28-days of onset were 1.13 (1.08–1.18), 1.15 (1.07–1.25) and 1.09 (0.97–1.22), while odds in GNBSIs with an associated COVID-19 infection were 2.45 (2.26–2.66), 2.96 (2.62–3.34) and 3.15 (2.61–3.80), respectively. Asian patients with an associated COVID-19 infection were more likely to die during the pandemic compared to White patients (<em>E. coli</em>: OR 1.28 (0.95–1.71); <em>Klebsiella</em> spp. OR 1.59 (1.20–2.11); <em>P. aeruginosa</em>: OR 2.02 (1.23–3.31)).</p></div><div><h3>Conclusions</h3><p>Patients suffering from a GNBSI had increased risk of death during the pandemic, with the risk higher in patients with an associated COVID-19 infection.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106256"},"PeriodicalIF":14.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001907/pdfft?md5=bd503fcccf76cb926880cc1c7e0875de&pid=1-s2.0-S0163445324001907-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes","authors":"FD Richard Hobbs ,&nbsp;Oghenekome A. Gbinigie-Thompson ,&nbsp;Milensu Shanyinde ,&nbsp;Ly-Mee Yu ,&nbsp;Victoria Harris ,&nbsp;Jienchi Dorward ,&nbsp;Gail Hayward ,&nbsp;Benjamin R. Saville ,&nbsp;Nicholas S. Berry ,&nbsp;Philip H. Evans ,&nbsp;Nicholas PB Thomas ,&nbsp;Mahendra G. Patel ,&nbsp;Duncan Richards ,&nbsp;Oliver Van Hecke ,&nbsp;Michelle A. Detry ,&nbsp;Christina T. Saunders ,&nbsp;Mark Fitzgerald ,&nbsp;Jared Robinson ,&nbsp;Charlotte Latimer-Bell ,&nbsp;Julie Allen ,&nbsp;Christopher C. Butler","doi":"10.1016/j.jinf.2024.106248","DOIUrl":"10.1016/j.jinf.2024.106248","url":null,"abstract":"<div><h3>Background</h3><p>Evidence for the effect of favipiravir treatment of acute COVID-19 on recovery, hospital admissions and longer-term outcomes in community settings is limited.</p></div><div><h3>Methods</h3><p>In this multicentre. open-label, multi-arm, adaptive platform randomised controlled trial participants aged ≥18 years in the community with a positive test for SARS-CoV-2 and symptoms lasting ≤14 days were randomised to: usual care; usual care plus favipiravir tablets (loading dose of 3600 mg in divided doses on day one, then 800 mg twice a day for four days); or, usual care plus other interventions. Co-primary endpoints were time to first self-reported recovery and hospitalisation/death related to COVID-19, within 28 days, analysed using Bayesian models. Recovery at six months was the primary longer-term outcome. Trial registration: ISRCTN86534580.</p></div><div><h3>Findings</h3><p>The primary analysis model included 8811 SARS-CoV-2 positive mostly COVID vaccinated participants, randomised to favipiravir (n = 1829), usual care (n = 3256), and other treatments (n = 3726). Time to self-reported recovery was shorter in the favipiravir group than usual care (estimated hazard ratio 1·23 [95% credible interval 1·14 to 1·33]), a reduction of 2·98 days [1·99 to 3·94] from 16 days in median time to self-reported recovery for favipiravir versus usual care alone. COVID-19 related hospitalisations/deaths were similar (estimated odds ratio 0·99 [0·61 to 1·61]; estimated difference 0% [−0·9% to 0·6%]). 14 serious adverse events occurred in the favipiravir group and 4 in usual care. By six months, the proportion feeling fully recovered was 74·9% for favipiravir versus 71·3% for usual care (RR = 1·05, [1·02 to 1·08]).</p></div><div><h3>Interpretation</h3><p>In this open-label trial in a largely vaccinated population with COVID-19 in the community, favipiravir did not reduce hospital admissions, but shortened time to recovery and had a marginal positive impact on long term outcomes.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":"89 4","pages":"Article 106248"},"PeriodicalIF":14.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001828/pdfft?md5=6a5cc3d76c2a0789177fd542006c3fd1&pid=1-s2.0-S0163445324001828-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142114304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}